Equillium, Inc.
(NASDAQ : EQ)

( )
EQ After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -2.31%324.210.0%$4670.09m
BNTXBioNTech SE -1.06%247.680.0%$730.32m
NVAXNovavax, Inc. -4.59%161.9579.4%$715.24m
AMGNAmgen, Inc. 0.51%207.841.4%$575.65m
SNSSSunesis Pharmaceuticals, Inc. -7.57%6.470.7%$452.28m
GILDGilead Sciences, Inc. -0.76%67.631.0%$426.45m
REGNRegeneron Pharmaceuticals, Inc. -0.43%553.242.7%$408.99m
ILMNIllumina, Inc. 0.45%409.933.3%$392.87m
CCXIChemoCentryx, Inc. -7.04%34.472.9%$387.64m
XLRNAcceleron Pharma, Inc. 0.50%172.945.3%$345.45m
VRTXVertex Pharmaceuticals, Inc. -0.07%181.771.9%$259.59m
BIIBBiogen, Inc. -1.43%281.191.7%$243.39m
OCGNOcugen, Inc. -13.83%8.660.0%$178.37m
XENEXenon Pharmaceuticals, Inc. 2.12%33.660.4%$178.19m
JSPRJasper Therapeutics, Inc. 31.57%16.420.0%$158.53m

Company Profile

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. Its product pipeline includes EQ001, which is a monoclonal antibody that selectively targets the novel immune checkpoint receptor CD6. The company was founded by Daniel Mark Bradbury, Bruce D. Steel, and Stephen Connelly on March 16, 2017 and is headquartered in La Jolla, CA.